121 related articles for article (PubMed ID: 15982582)
21. How is (68)Ga labeling of macrocyclic chelators influenced by metal ion contaminants in (68)Ge/(68)Ga generator eluates?
Šimeček J; Hermann P; Wester HJ; Notni J
ChemMedChem; 2013 Jan; 8(1):95-103. PubMed ID: 23136062
[TBL] [Abstract][Full Text] [Related]
22. Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes.
Cooper MS; Sabbah E; Mather SJ
Nat Protoc; 2006; 1(1):314-7. PubMed ID: 17406251
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, pharmacokinetics, and biodistribution of 67GA deferoxamineacetyl-cysteinylbiotin.
Hashmi M; Rosebrough SF
Drug Metab Dispos; 1995 Dec; 23(12):1362-7. PubMed ID: 8689944
[TBL] [Abstract][Full Text] [Related]
24. An antibody-desferrioxamine conjugate labelled with 67Ga.
Ward MC; Roberts KR; Babich JW; Bukhari MA; Coghlan G; Westwood JH; McCready VR; Ott RJ
Int J Rad Appl Instrum B; 1986; 13(5):505-7. PubMed ID: 3818312
[TBL] [Abstract][Full Text] [Related]
25. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
26. NODAPA-OH and NODAPA-(NCS)n: synthesis, 68Ga-radiolabelling and in vitro characterisation of novel versatile bifunctional chelators for molecular imaging.
Riss PJ; Kroll C; Nagel V; Rösch F
Bioorg Med Chem Lett; 2008 Oct; 18(20):5364-7. PubMed ID: 18835159
[TBL] [Abstract][Full Text] [Related]
27. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.
Chang MY; Seideman J; Sofou S
Bioconjug Chem; 2008 Jun; 19(6):1274-82. PubMed ID: 18505278
[TBL] [Abstract][Full Text] [Related]
28. New insight into the influence of carob extract and gallic acid on hemin induced modulation of HT29 cell growth parameters.
Klenow S; Glei M
Toxicol In Vitro; 2009 Sep; 23(6):1055-61. PubMed ID: 19527781
[TBL] [Abstract][Full Text] [Related]
29. Succinylated polylysine as a possible link between an antibody molecule and deferoxamine.
Slinkin MA; Klibanov AL; Khaw BA; Torchilin VP
Bioconjug Chem; 1990; 1(4):291-5. PubMed ID: 2096922
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
31. Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI).
Orlova A; Bruskin A; Sivaev I; Sjöberg S; Lundqvist H; Tolmachev V
Anticancer Res; 2006; 26(2A):1217-23. PubMed ID: 16619527
[TBL] [Abstract][Full Text] [Related]
32. Novel trihydroxamate-containing peptides: design, synthesis, and metal coordination.
Ye Y; Liu M; Kao JL; Marshall GR
Biopolymers; 2006; 84(5):472-89. PubMed ID: 16705688
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of oxidation-responsive alginate-deferoxamine conjugates with increased stability and low toxicity.
Tian M; Chen X; Gu Z; Li H; Ma L; Qi X; Tan H; You C
Carbohydr Polym; 2016 Jun; 144():522-30. PubMed ID: 27083844
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of labeling efficiency, biological activity and biodistribution among 125I-, 67Ga-DTPA-and 67Ga-DFO-lectins.
Kojima S; Jay M
Eur J Nucl Med; 1987; 13(7):366-70. PubMed ID: 3428286
[TBL] [Abstract][Full Text] [Related]
35. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
36. Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent.
Motta-Hennessy C; Eccles SA; Dean C; Coghlan G
Eur J Nucl Med; 1985; 11(6-7):240-5. PubMed ID: 4076230
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional regulation of IL-8 by iron chelator in human epithelial cells is independent from NF-kappaB but involves ERK1/2- and p38 kinase-dependent activation of AP-1.
Choi EY; Park ZY; Choi EJ; Oh HM; Lee S; Choi SC; Lee KM; Im SH; Chun JS; Jun CD
J Cell Biochem; 2007 Dec; 102(6):1442-57. PubMed ID: 17471497
[TBL] [Abstract][Full Text] [Related]
38. Deferoxamine mesylate enhancement of 67Ga tumor-to-blood ratios and tumor imaging.
Koizumi K; Tonami N; Hisada K
Eur J Nucl Med; 1982; 7(5):229-33. PubMed ID: 6954069
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications.
Chappell LL; Deal KA; Dadachova E; Brechbiel MW
Bioconjug Chem; 2000; 11(4):510-9. PubMed ID: 10898572
[TBL] [Abstract][Full Text] [Related]
40. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
